Abstract
The Global Initiative for Asthma (GINA) was launched in 1993 under the auspices of the National Heart, Lung and Blood Institute, NIH, USA, and the World Health Organization, to produce a global strategy on asthma management and prevention. Now constituted as a non-profit entity, it continues to produce on an annual basis, the most widely cited evidence-based report on the optimal management of asthma both in adults and children intended for global use. Although the GINA report is often viewed and used as an asthma treatment guideline, it is designed to be a clinically oriented strategy document that supports the development of practice guidelines in different countries and regions.
Other GINA products, including the report's Pocket Guides, teaching slide kits, and implementation tools are also offered free of charge for public use. The GINA Scientific Committee comprises recognised international experts from primary, secondary and tertiary centers of care who are actively involved in both the care of patients and research in asthma. The GINA Assembly is a forum for exchange of scientific information and discussions on initiatives to improve asthma care in various countries, focussing on implementation strategies. GINA plays a role in shaping research on the diagnosis and treatment of asthma and informs the development of point of care practice guides and decision support tools. GINA supports the objectives of raising awareness of asthma, improving access to therapy and quality of care for asthmatic patients, in addition to present and promote continuously updated evidence-based treatment approaches for global use.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Boulet reports and LOUIS-PHILIPPE BOULET
Disclosure of potential conflicts of interest - last 3 years
Research grants for participation to multicentre studies
AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi, Takeda.
Support for research projects introduced by the investigator
AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Takeda.
Consulting and advisory boards
Astra Zeneca, Novartis, Methapharm.
Royalties
Co-author of “Up-To-Date” (occupational asthma)
Patents
None.
Nonprofit grants for production of educational materials
AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis.
Conference fees
AstraZeneca, GlaxoSmithKline, Merck, Novartis.
Support for participation in conferences and meetings
Novartis, Takeda.
Other participations
Past president and Member of the Canadian Thoracic Society Respiratory Guidelines Committee;
Chair of the Board of Directors of the Global Initiative for Asthma (GINA)
Chair of Global Initiative for Asthma (GINA) Guidelines Dissemination and Implementation Committee;
Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health;
Member of scientific committees for the American College of Chest Physicians, American Thoracic Society, European Respiratory Society and the World Allergy Organization;
1st Vice-President of the Global Asthma Organization «InterAsma».
Conflict of interest: Dr. Reddel reports grants and personal fees from AstraZeneca, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from Merck, grants and personal fees from Novartis, personal fees from Teva, personal fees from Mundipharma, personal fees from Boehringer Ingelheim, outside the submitted work; and Dr Reddel is Chair of the GINA Scientific Committee.
Conflict of interest: Dr. Bateman is a member of the Science Committee and Board of GINA. He reports personal fees from AstraZeneca, Boehringer Ingelheim, Sanofi Regeneron, Novartis, Vectura, Cipla, Menarini, ALK, ICON, and grants to his institution from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann le Roche, Sanofi-Aventis, TEVA and Novartis, outside the submitted work.
Conflict of interest: Dr. Pedersen reports personal fees from Astrazeneca, personal fees from ALK, personal fees from Thermofisher, outside the submitted work.
Conflict of interest: Dr. FitzGerald reports other from GINA, during the conduct of the study; and Member of GINA Executive and Science committees.
Conflict of interest: M. O'Byrne
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2019